AR034255A1 - Combinaciones de carboxialquileter, inhibidor de acat - Google Patents
Combinaciones de carboxialquileter, inhibidor de acatInfo
- Publication number
- AR034255A1 AR034255A1 ARP010102688A ARP010102688A AR034255A1 AR 034255 A1 AR034255 A1 AR 034255A1 AR P010102688 A ARP010102688 A AR P010102688A AR P010102688 A ARP010102688 A AR P010102688A AR 034255 A1 AR034255 A1 AR 034255A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- branched
- straight
- substituted
- hydrogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- -1 carboxyalkyl ether Chemical compound 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 abstract 1
- 101710181187 Liver carboxylesterase 1 Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- SWYZGLWCQFMQJW-UHFFFAOYSA-N phenoxy hypofluorite Chemical compound FOOC1=CC=CC=C1 SWYZGLWCQFMQJW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición farmacéutica que comprende: a) un carboxialquiléter; b) un inhibidor de acilcoenzima A: colesterol aciltransferasa (ACAT) o sus sales farmacéuticamente aceptables; y c) un portador o diluyente. El portador de ACAT tiene la fórmula (1) donde: X e Y son oxígeno, azufre, y (CR'R'')n; n es un número entero de 1 a 4; y R' y R'' son hidrógeno, alquilo, alcoxi, halógeno, hidroxi, aciloxi, cicloalquilo, fenilo optativamente sustituido, o R' y R'' juntos forman un espirocicloalquilo o un carbonilo; con la condición que al menos uno de X e Y es (CR'R'')n y que cuando X e Y son ambos (CR'R'')n, y R' y R'' son hidrógeno y n es 1, R1 y R2 son arilo; R es hidrógeno, alquilo C1-8 recto o ramificado o bencilo; R1 y R2 son: a) fenilo o fenoxi no sustituido o sustituido con 1 a 5 grupos fenilo, alquilo C1-6 recto o ramificado, alcoxi C1-6 recto o ramificado, fenoxi, hidroxi, flúor, cloro, bromo, nitro, trifluorometilo, -COOH, -COO(alquilo C1-4 recto o ramificado), -(CH2)pNR3R4 donde p es 0 ó 1, y R3 y R4 son hidrógeno o alquilo C1-4 recto o ramificado; b) 1- ó 2-naftilo no sustituido o sustituido con 1 a 3 grupos como en (a); c) arilalquilo; d) alquilo C1-20 recto o ramificado, saturado o con 1-3 enlaces dobles; y e) adamatilo o cicloalquilo con cicloalquilo C3-6. El carboxialquiléter tiene la fórmula (2) donde: n y m son números enteros de 2 a 9; R1, R2, R3 y R4 son alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y R1 y R2 junto con el carbono al cual están unidos, y R3 y R4 junto con el carbono al cual están unidos, pueden completar un anillo carbocíclico C3-6; Y1 e Y2 son COOH, CHO, tetrazol y COOR5; R5 es alquilo C1-6, alquenilo C2-6, y alquinilo C2-6; los grupos alquilo, alquenilo y alquinilo pueden ser sustituidos con 1ó 2 grupos halo, hidroxi, alcoxi C1-6 y fenilo. Una primer composición farmacéutica para uso con una segunda composición farmacéutica que comprenden un inhibidor de ACAT y un carboxialquiléter y conjunto correspondiente con formas de dosificación unitarias. Estas composiciones son útiles para tratar dislipidemias y síndromes isquémicos, ataques cardíacos y trastornos cardiovasculares relacionados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21005600P | 2000-06-07 | 2000-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034255A1 true AR034255A1 (es) | 2004-02-18 |
Family
ID=22781424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102688A AR034255A1 (es) | 2000-06-07 | 2001-06-06 | Combinaciones de carboxialquileter, inhibidor de acat |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1292363A2 (es) |
| JP (1) | JP2003535125A (es) |
| AR (1) | AR034255A1 (es) |
| AU (1) | AU2001263003A1 (es) |
| BR (1) | BR0111428A (es) |
| CA (1) | CA2413906A1 (es) |
| GT (1) | GT200100106A (es) |
| MX (1) | MXPA02010762A (es) |
| PA (1) | PA8518601A1 (es) |
| PE (1) | PE20020265A1 (es) |
| SV (1) | SV2002000466A (es) |
| TN (1) | TNSN01085A1 (es) |
| UY (1) | UY26752A1 (es) |
| WO (1) | WO2001093845A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7387236B2 (en) | 2001-10-09 | 2008-06-17 | Delaware Capital Formation, Inc. | Dispensing of currency |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU762124B2 (en) * | 1998-01-28 | 2003-06-19 | Warner-Lambert Company | Method for treating Alzheimer's disease |
-
2001
- 2001-05-08 MX MXPA02010762A patent/MXPA02010762A/es not_active Application Discontinuation
- 2001-05-08 JP JP2002501418A patent/JP2003535125A/ja active Pending
- 2001-05-08 AU AU2001263003A patent/AU2001263003A1/en not_active Abandoned
- 2001-05-08 CA CA002413906A patent/CA2413906A1/en not_active Abandoned
- 2001-05-08 EP EP01937250A patent/EP1292363A2/en not_active Withdrawn
- 2001-05-08 WO PCT/US2001/014804 patent/WO2001093845A2/en not_active Ceased
- 2001-05-08 BR BR0111428-0A patent/BR0111428A/pt not_active IP Right Cessation
- 2001-05-24 SV SV2001000466A patent/SV2002000466A/es not_active Application Discontinuation
- 2001-06-05 PA PA20018518601A patent/PA8518601A1/es unknown
- 2001-06-05 TN TNTNSN01085A patent/TNSN01085A1/en unknown
- 2001-06-05 UY UY26752A patent/UY26752A1/es not_active Application Discontinuation
- 2001-06-05 GT GT200100106A patent/GT200100106A/es unknown
- 2001-06-05 PE PE2001000517A patent/PE20020265A1/es not_active Application Discontinuation
- 2001-06-06 AR ARP010102688A patent/AR034255A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT200100106A (es) | 2002-05-20 |
| JP2003535125A (ja) | 2003-11-25 |
| CA2413906A1 (en) | 2001-12-13 |
| EP1292363A2 (en) | 2003-03-19 |
| BR0111428A (pt) | 2003-06-10 |
| AU2001263003A1 (en) | 2001-12-17 |
| PA8518601A1 (es) | 2002-07-30 |
| TNSN01085A1 (en) | 2005-11-10 |
| SV2002000466A (es) | 2002-04-03 |
| MXPA02010762A (es) | 2003-03-10 |
| WO2001093845A3 (en) | 2002-10-10 |
| WO2001093845A2 (en) | 2001-12-13 |
| UY26752A1 (es) | 2001-07-31 |
| PE20020265A1 (es) | 2002-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061341A1 (es) | Compuesto de 5-amino-n-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)-fuorofenil]-1h-pirazol-4-carboxanmida, su uso para la preparacion de un medicamento composicion farmaceutica que lo comprende, proceso y compuestos intermediarios para su preparacion | |
| ES2188957T3 (es) | N-(4-(heteroarilmetil)fenil)-heteroarilaminas. | |
| AR070861A1 (es) | Uso de terapia de combinacion con antagonistas de c-met y egfr | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| AR059178A1 (es) | Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. | |
| CO6170406A2 (es) | Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas | |
| ECSP045491A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| ATE506354T1 (de) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
| CL2008002998A1 (es) | Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion. | |
| UY30736A1 (es) | Compuestos quimicos 537 | |
| SV2003000633A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7 | |
| AR041732A1 (es) | Metodos y composiciones que proveen color permanente para el cabello mediante la utilizacion de sales de carbonato y uilizando precursores de acido percarbamico | |
| AR062620A1 (es) | Insecticidas n- sustituidos (2-sustituidos-1.3- tiazol) alquil sulfoximinas | |
| AR064241A1 (es) | Metodos para el tratamiento de la depresion | |
| AR017851A1 (es) | Composicion farmaceutica que comprende un eter carboxialquilico y una estatina, primera composicion farmaceutica para el uso con una segunda composicionfarmaceutica para lograr un efecto hipolipidemico y controlar el riesgo cardiaco adverso en un mamifero y conjunto para lograr dichos efectos terape | |
| UY39761A (es) | Terapias combinadas | |
| CO4950553A1 (es) | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion | |
| MX2009005145A (es) | Combinaciones de herbicidas con sulfonilureas especiales. | |
| AR044453A1 (es) | Derivados de metoxi-pirazin-tienil sulfonamida | |
| AR034255A1 (es) | Combinaciones de carboxialquileter, inhibidor de acat | |
| AR050576A1 (es) | Oxadiazolonas con actividad agonista de ppar-delta. composiciones farmaceuticas. | |
| CO5700779A2 (es) | Un proceso para la preparación de oxi-(1h)-quinolin-2-onas 5-(haloacetil)-8-sustituidas | |
| AR025093A1 (es) | Nuevos derivados de tetrazolinona | |
| MX2010008448A (es) | Compuesto de bencilpiperizina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |